StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project:[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
Zurück
HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 57504649Erstellt: 30. Oktober 2026

Azetidin-3-ol;hydron;chloride

AZETIDIN-3-OL HYDROCHLORIDE · 3-AZETIDINOL HYDROCHLORIDE · 3-HYDROXYAZETIDINE HCL · Azetidin-3-ol hydrochloride, 3-Hydroxyazetane hydrochloride · AZETAN-2-ONE · BUTTPARK 75\04-67 · Azetidine-3-ol.Hcl · Baricitinib-009-HCl

https://huagongshe.com/de/chemical/57504649

Molekülstruktur von Azetidin-3-ol;hydron;chloride

Identifikatoren & physikalische Daten

CAS No.18621-18-6
SummenformelC3H8ClNO
Durchschnittliche Molmasse109,55 g/mol
Monoisotopische Masse109,0294416 g/mol
SMILESOC1CNC1.[Cl-].[H+]
InChIKeyUQUPQEUNHVVNKW-UHFFFAOYSA-N
PubChem CID57504649

Chemische & physikalische Eigenschaften

Polarare Oberfläche (TPSA)32,3
H-Brücken-Donoren3
H-Brücken-Akzeptoren3
Frei drehbare Bindungen0
Schwere Atome6
Formalladung0
Komplexität33,9
Schmelzpunkt85-90 °C
LagerbedingungenKeep in dark place,Sealed in dry,Room Temperature
LöslichkeitDMSO (Slightly), Methanol (Slightly), Water (Slightly)Soluble in water, DMSO, methanol.
AggregatzustandSolid
FarbeWhite to Off-White
StabilitätHygroscopic
InChIInChI=1S/C3H7NO.ClH/c5-3-1-4-2-3/h3-5H,1-2H21H
InChIKeyUQUPQEUNHVVNKW-UHFFFAOYSA-N
SMILESC1(O)CNC1.Cl
CAS Datenbank18621-18-6(CAS DataBase Reference)

Sicherheit & Vorschriften

Wassergefährdungsklasse (WGK)3
UN-TransportnummerUN1759
Zollcode29339900
R-Sätze (R)36/37/38-41-37/38-22
GefahrensymboleC,Xi,Xn
hazard_noteHarmful/Corrosive
Sicherheitshinweise (S)26-36/37/39
GefahrenklasseIRRITANTAcute Tox. 4 OralEye Dam. 1Skin Irrit. 2STOT SE 3
Lagerklasse11 - Combustible Solids

Anwendungen & Verwendung

Beschreibung

3-hydroxyazaecyclobutane hydrochloride is an azaecyclobutane compound that is an important intermediate in the synthesis of Brectinib, which is obtained through a multi-step reaction. Brectinib was approved by the European Union. The monotherapy or in combination with methotrexate for the treatment of adult patients with moderate to severe active rheumatoid arthritis with inadequate or intolerant relief from one or more antirheumatic drugs. It is also the first JAK inhibitor approved in the European Union for the treatment of rheumatoid arthritis.